MindMaze Therapeutics Holding (RLFTF) Fair Value & Analysis
Health Care · US · Market cap $3.7M
Fair value as of: Jun 25, 2026
Analysis
MindMaze Therapeutics Holding (RLFTF) currently trades at $0.2850, while our model-based Fair Value estimate is $0.3061 — implying the stock looks roughly 7.4% undervalued today. We read business quality at 92/100 (high quality), in the Health Care sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was …
Open the full interactive analysis →
Frequently asked questions
Is MindMaze Therapeutics Holding (RLFTF) undervalued?
What is the fair value of RLFTF?
What is the quality score of RLFTF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.